Greater China

Shanghai Dongzheng Automotive Finance Co has kicked off the roadshow for its up to HK$3.36bn ($428m) Hong Kong IPO.

David Morton, the former head of corporates, financials and multinational banking (CFMB) at HSBC, has announced his retirement.

China’s Frontage Holdings Corp, which provides support to pharmaceutical companies, has refiled a draft IPO prospectus with Hong Kong’s stock exchange.

GLP has closed a Rmb3.3bn ($490m) nine year Panda bond, after scrapping an earlier plan to sell a dual-tranche deal.

Asia’s primary bond market has started the year with a bang. New dollar issuance has been steady, and issuers are getting increasingly confident in their ability to court investors with what can only be considered bull market deals. But the market isn’t strong enough to allow issuers to get away with such aggressive terms for long.

Chinese local government-owned power generator Chongqing Energy Investment Group Co wrapped up its inaugural offshore bond, finding enough demand to support an aggressive price tightening.

Hong Kong Exchanges and Clearing (HKEX) will launch futures contracts on the A-share segment of the MSCI China Index.

Shanghai Fudan-Zhangjian Bio-Pharmaceutical Co has become the first Hong Kong-listed company to announce that it wants to float on China’s hotly-anticipated technology board.

In this round-up, both exports and imports slowed in February, the US and China have not started preparing for a deal-signing summit and the People’s Bank of China (PBoC) has released its February financial data.

Hong Kong Exchanges and Clearing (HKEX) signed an agreement with MSCI on Monday to introduce a futures contract covering the MSCI China shares index.

China-based biotechnology firm Mabpharm is looking for the greenlight to list in Hong Kong, having filed a draft IPO prospectus with the city’s stock exchange.

Tesla has raised the equivalent of $521m from the loan market, helping fund its Shanghai factory.